Nissan
Chemical Reports Positive Phase IIb study results for NM-702 in
Intermittent Claudication, 03/13/06
aRigen,
Japanese Bioventure Company, Announces Start of US Clinical Study of
Novel Anti-Staph Antibiotic By Catalyst (CRO), 09/21/04
OmniComm
Systems (TrialMaster®) and Catalyst Pharmaceutical Research
Team-Up to Expedite Phase I Trial Data Collection and Reporting,
09/03/04
Catalyst
CRO Joins Spacelabs Medical Data in Strategic Partnership,
08/16/04
BioAsia
Licensing &
Deal-Making Summit to Focus on Life Sciences Partnering Among American,
Japanese, Chinese and Taiwanese Companies in San Diego August 2-3, 200405/11/04
Bridging
the Cultural Gap: Catalyst Pharmaceutical Reserch helps Asian drug
companies gain U.S. approval for products, 05/07/04
Catalyst
Pharma Group Inc. Completes Acquisition of Healthcare Discoveries Inc.,
Phase I Unit, 03/08/04
Novel
Agent for Intermittent Claudication NM-702, Shows Clinical Benefit
Trends in Phase II Clinical Study, 11/12/03
Sponsor
& CRO
Clinical Outsourcing & Partnerships Conference &
Exposition to
Attract Pharma and Service Provider Companies on September 22-24, 2003
in Scottsdale, AZ, 07/23/03
Nissan
Chemical Announces Start of Phase IIb Clinical Study in Intermittent
Claudication,05/07/03
Catalyst
Announces Licensing Alliance for Cardiovascular Therapeutic,
03/11/03
